Letter to the Editor referring to the manuscript entitled: 'Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study' recently reported by Fleming et al., (Gynecol Oncol., 116;15-20;2010).

摘要

I have read with interest the paper published by Fleming et al., reporting the results of GOG181B, a Phase II trial on trastuzumab in women with advanced or recurrent HER-2eu-positive endometrial carcinoma [ 1 ]. In this report the Authors concluded that Trastuzumab as a single agent did not demonstrate activity against endometrial carcinomas harboring HER-2eu overexpression or HER-2eu gene amplification. Unfortunately, in the study it is not made sufficiently clear that the reported lack of activity of trastuzumab against advanced or recurrent endometrial cancer, including type II endometrial cancers (i.e., serous papillary carcinoma, USPC), cannot either be supported or refuted by the analysis presented. Such conclusions may therefore be misleading.